These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 20004272)

  • 1. The efficacy and safety of a low-dose, 91-day, extended-regimen oral contraceptive with continuous ethinyl estradiol.
    Kroll R; Reape KZ; Margolis M
    Contraception; 2010 Jan; 81(1):41-8. PubMed ID: 20004272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of an ascending-dose, extended-regimen levonorgestrel/ethinyl estradiol combined oral contraceptive.
    Portman DJ; Kaunitz AM; Howard B; Weiss H; Hsieh J; Ricciotti N
    Contraception; 2014 Apr; 89(4):299-306. PubMed ID: 24576794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous, daily levonorgestrel/ethinyl estradiol vs. 21-day, cyclic levonorgestrel/ethinyl estradiol: efficacy, safety and bleeding in a randomized, open-label trial.
    Teichmann A; Apter D; Emerich J; Greven K; Klasa-Mazurkiewicz D; Melis GB; Spaczynski M; Grubb GS; Constantine GD; Spielmann D
    Contraception; 2009 Dec; 80(6):504-11. PubMed ID: 19913143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter, uncontrolled clinical investigation of the contraceptive efficacy, cycle control, and safety of a new low dose oral contraceptive containing 20 micrograms ethinyl estradiol and 100 micrograms levonorgestrel over six treatment cycles.
    Bannemerschult R; Hanker JP; Wünsch C; Fox P; Albring M; Brill K
    Contraception; 1997 Nov; 56(5):285-90. PubMed ID: 9437556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of a 21/7-active combined oral contraceptive with continuous low-dose ethinyl estradiol.
    Kroll R; Ackerman R; Feldman R; Howard B; Weiss H; Hsieh J; Ricciotti N
    Contraception; 2016 Mar; 93(3):249-56. PubMed ID: 26499407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results.
    Archer DF; Jensen JT; Johnson JV; Borisute H; Grubb GS; Constantine GD
    Contraception; 2006 Dec; 74(6):439-45. PubMed ID: 17157099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A look at the long-term safety of an extended-regimen OC.
    Davis MG; Reape KZ; Hait H
    J Fam Pract; 2010 May; 59(5):E3. PubMed ID: 20544040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of pituitary-ovarian axis suppression with three oral contraceptive regimens.
    Vandever MA; Kuehl TJ; Sulak PJ; Witt I; Coffee A; Wincek TJ; Reape KZ
    Contraception; 2008 Mar; 77(3):162-70. PubMed ID: 18279685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Extended 30 μg Ethinyl Estradiol with Continuous Low-Dose Ethinyl Estradiol and Cyclic 20 μg Ethinyl Estradiol Oral Contraception on Adolescent Bone Density: A Randomized Trial.
    Gersten J; Hsieh J; Weiss H; Ricciotti NA
    J Pediatr Adolesc Gynecol; 2016 Dec; 29(6):635-642. PubMed ID: 27287084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bleeding profile of a flexible extended regimen of ethinylestradiol/drospirenone in US women: an open-label, three-arm, active-controlled, multicenter study.
    Jensen JT; Garie SG; Trummer D; Elliesen J
    Contraception; 2012 Aug; 86(2):110-8. PubMed ID: 22281416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol.
    Anderson FD; Gibbons W; Portman D
    Contraception; 2006 Mar; 73(3):229-34. PubMed ID: 16472561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel.
    Ahrendt HJ; Makalová D; Parke S; Mellinger U; Mansour D
    Contraception; 2009 Nov; 80(5):436-44. PubMed ID: 19835717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of a 28-day oral contraceptive with 7 days of low-dose estrogen in place of placebo.
    Poindexter A; Reape KZ; Hait H
    Contraception; 2008 Aug; 78(2):113-9. PubMed ID: 18672111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and bleeding profile of continuous levonorgestrel 90 mcg/ethinyl estradiol 20 mcg based on 2 years of clinical trial data in Canada.
    Reid RL; Fortier MP; Smith L; Mirkin S; Grubb GS; Constantine GD
    Contraception; 2010 Dec; 82(6):497-502. PubMed ID: 21074011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian activity and safety of a novel levonorgestrel/ethinyl estradiol continuous oral contraceptive regimen.
    Archer DF; Kovalevsky G; Ballagh SA; Grubb GS
    Contraception; 2009 Sep; 80(3):245-53. PubMed ID: 19698816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of the pharmacokinetic profile of an ascending-dose, extended-regimen combined oral contraceptive to those of other extended regimens.
    Darwish M; Bond M; Ricciotti N; Hsieh J; Fiedler-Kelly J; Grasela T
    Reprod Sci; 2014 Nov; 21(11):1401-10. PubMed ID: 24647707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and tolerability of a new low-dose contraceptive patch in obese and nonobese women.
    Kaunitz AM; Archer DF; Mishell DR; Foegh M
    Am J Obstet Gynecol; 2015 Mar; 212(3):318.e1-8. PubMed ID: 25220709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Body weight does not impact pregnancy rates during use of a low-dose extended-regimen 91-day oral contraceptive.
    Westhoff CL; Hait HI; Reape KZ
    Contraception; 2012 Mar; 85(3):235-9. PubMed ID: 22067763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new low-dose monophasic combination oral contraceptive (Alesse) with levonorgestrel 100 micrograms and ethinyl estradiol 20 micrograms. North American Levonorgestrel Study Group (NALSG).
    Archer DF; Maheux R; DelConte A; O'Brien FB
    Contraception; 1997 Mar; 55(3):139-44. PubMed ID: 9115001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in reporting Pearl Indices in the United States and Europe: Focus on a 91-day extended-regimen combined oral contraceptive with low-dose ethinyl estradiol supplementation.
    Lobo Abascal P; Luzar-Stiffler V; Giljanovic S; Howard B; Weiss H; Trussell J
    Eur J Contracept Reprod Health Care; 2016; 21(1):88-91. PubMed ID: 26115381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.